ZIOPHARM Oncology Inc. (Nasdaq:ZIOP)
June 12th, 2019
Amidst falling markets ZIOPHARM Oncology Inc. closed the day up $0.46 Wednesday which equals a 10.38% jump, closing at $4.89. Furthermore it hit a new 52 week high of $5.00. The stock continues to trade well at 213.46% of its 52 week low of $1.56. In addition to finishing higher, trading volumes were solid at 277.00% of normal which can indicate investors see opportunities.
ZIOP outperformed the rest of the Healthcare sector which went up 0.51% today.
Results from 4 analysts suggest that ZIOPHARM Oncology Inc. could increase significantly (32.28%).
The market sectors were mixed Wednesday with a majority of the sectors trending up. Utilities saw the biggest increase of the day (1.33%), while the Energy sector saw the biggest drop (-1.44%). Information Technology has seen the biggest year-to-date gain of 23.77%.
Energy and Financials both saw turn-arounds from their five day positive performances with Energy dropping -1.44%.
- Utilities, up 1.33%.
- Healthcare, up 0.51%.
- Materials, up 0.31%.
- Real Estate, up 0.26%.
- Industrials, up 0.20%.
- Consumer Staples, up 0.04%.
- Consumer Discretionary, down -0.11%.
- Communication Services, down -0.28%.
- Information Technology, down -0.58%.
- Financials, down -0.95%.
- Energy, down -1.44%.
ZIOPHARM Oncology Inc. Info
ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient’s immune system to attack cancer cells. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, to treat patients with recurrent glioblastoma and breast cancer. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; research and development agreement with the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.